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Summary
Background Invasive meningococcal disease (IMD) is a worldwide health issue that is potentially preventable with 
vaccination. In view of its sporadic nature and the high diversity of Neisseria meningitidis, epidemiological surveillance 
incorporating detailed isolate characterisation is crucial for eﬀ ective control and understanding the evolving 
epidemiology of IMD. The Meningitis Research Foundation Meningococcus Genome Library (MRF-MGL) exploits 
whole-genome sequencing (WGS) for this purpose and presents data on a comprehensive and coherent IMD isolate 
collection from England and Wales via the internet. We assessed the contribution of these data to investigating IMD 
epidemiology.
Methods WGS data were obtained for all 899 IMD isolates available for England and Wales in epidemiological years 
2010–11 and 2011–12. The data had been annotated at 1720 loci, analysed, and disseminated online. Information was 
also available on meningococcal population structure and vaccine (Bexsero, GlaxoSmithKline, Brentford, Middlesex, 
UK) antigen variants, which enabled the investigation of IMD-associated genotypes over time and by patients’ age 
groups. Population genomic analyses were done with a hierarchical gene-by-gene approach.
Findings The methods used by MRF-MGL eﬃ  ciently characterised IMD isolates and information was provided in 
plain language. At least 20 meningococcal lineages were identiﬁ ed, three of which (hyperinvasive clonal complexes 
41/44 [lineage 3], 269 [lineage 2], and 23 [lineage 23]) were responsible for 528 (59%) of IMD isolates. Lineages were 
highly diverse and showed evidence of extensive recombination. Speciﬁ c lineages were associated with IMD in 
particular age groups, with notable diversity in the youngest and oldest individuals. The increased incidence of IMD 
from 1984 to 2010 in England and Wales was due to successive and concurrent epidemics of diﬀ erent lineages. 
Genetically, 74% of isolates were characterised as encoding group B capsules: 16% group Y, 6% group W, and 3% 
group C. Exact peptide matches for individual Bexsero vaccine antigens were present in up to 26% of isolates. 
Interpretation The MRF-MGL represents an eﬀ ective, broadly applicable model for the storage, analysis, and 
dissemination of WGS data that can facilitate real-time genomic pathogen surveillance. The data revealed information 
crucial to eﬀ ective deployment and assessment of vaccines against N meningitidis.
Funding Meningitis Research Foundation, Wellcome Trust, Public Health England, European Union.
Copyright © Hill et al. Open Access article distributed under the terms of CC BY.  
Introduction
Invasive meningococcal disease (IMD) caused by 
Neisseria meningitidis and encompassing meningitis and 
severe sepsis has been reported at varying rates 
worldwide for more than 200 years. N meningitidis is 
ordinarily a harmless commensal of the oropharynx. 
Disease incidence and asymptomatic carriage rates are 
age speciﬁ c. IMD is generally sporadic, with endemic 
rates being fewer than three cases per 100 000 of the 
general population, but hyperendemic outbreaks, intense 
localised outbreaks, and epidemics do occur. These 
ﬂ uctuations are thought to be due to interactions between 
N meningitidis biology, human susceptibility, and, 
possibly, evolution and spread of particularly invasive 
strains.1 Almost all IMD is caused by N meningitidis 
expressing the polysaccharide capsules that deﬁ ne 
serogroups A, B, C, W, X, and Y. Multilocus sequence 
typing (MLST) has shown that most disease is caused by 
temporally stable hyperinvasive lineages that correspond 
to speciﬁ c clonal complexes deﬁ ned by MLST.2
Control of IMD caused by several serogroups has been 
achieved in the UK by vaccination, such as meningococcal 
serogroup C conjugate vaccines, which led to herd 
immunity and a striking reduction in serogroup C disease 
(ﬁ gure 1).3 Because of poor immunogenicity and safety 
concerns, however, there are no equivalent vaccines 
against serogroup B polysaccharides. Serogroup-B-
substitute vaccines are based on proteins and often include 
outer-membrane vesicles.4 Vaccine coverage, therefore, 
depends on serological cross-reactivity. As such vaccines 
are introduced, com prehensive IMD surveillance is 
necessary to monitor antigenic variants, their expression, 
and their association with hyperinvasive lineages.
IMD has been reportable in England and Wales since 
1912. Even when alterations in reporting deﬁ nitions are 
taken into account, wide ﬂ uctuations in incidence are 
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evident (ﬁ gure 1). IMD reporting encompasses meningitis 
and septicaemia (the latter diagnosis referring to severe 
sepsis). Due to antibiotic therapy before microbiological 
culture from clinical specimens, around half of isolates 
are culture-conﬁ rmed cases (CCC). Linkage with 
epidemiological data shows that for clinically diagnosed 
cases in England and Wales the Public Health England 
(PHE) Meningococcal Reference Unit (MRU) receives 
98% of all samples, including isolates for CCC and 
specimens for non-culture-conﬁ rmed cases (NCCC).5,6 
Isolates are routinely characterised by serological and 
single-gene-sequencing technologies.5
The potential of whole-genome sequencing (WGS) for 
bacterial characterisation in clinical microbiology, 
transmission analyses, and studies of vaccine inter-
vention has been shown in several studies and case 
studies.7–14 For this potential to be realised in routine 
surveillance, however, sustainable, transparent, and 
compatible infrastructures are needed for data storage, 
analysis, and reporting. The Meningitis Research 
Foundation Meningococcus Genome Library (MRF-
MGL) presents such a framework. We used WGS data 
from all English and Welsh IMD isolates submitted to 
the PHE-MRU in 2 epi demiological years  to investigate 
IMD epidemiology.
Methods
Specimen collection
We used WGS data for all 899 IMD isolates submitted to 
PHE-MRU over the epidemiological years (July 1 to 
June 30) 2010–11 (501 isolates, 48% of laboratory-
conﬁ rmed cases) and 2011–12 (398 isolates, 52% of 
laboratory-conﬁ rmed cases; table 1). In agreement with 
the PHE Vaccine Preventable Invasive Bacterial Infec-
tions Forum, data on serogroup, year, and UK region of 
isolation were made publicly available for each isolate 
and other demographic data were available from the 
PHE-MRU on request.
Procedures
Isolate culture, DNA extraction, whole-genome 
sequencing, and de-novo draft-genome assembly were 
done with validated procedures described previously 
(appendix).7,8,15 Short-read sequences were deposited at 
the European Nucleotide Archive and assemblies were 
deposited in the MRF-MGL Neisseria Sequence Typing 
database,16,17 both of which have open access. Assemblies 
were annotated for 1720 locus entries deﬁ ned and 
indexed with MRF-MGL Neisseria Sequence Typing 
database numbers (NEIS),8,15 including those deﬁ ning 
genogroup, typing antigens, and vaccine antigens, and 
the 1605 full-length loci belonging to the N meningitidis 
core-genome MLST scheme (version 1.0).15 Features 
automatically reported by the database included antigen 
variants, MLST sequence types and clonal complexes, 
and ribosomal MLST sequence types based on 
49 N meningitidis loci.18 Single MLST locus sequences 
were interrupted by the ends of contiguous sequences in 
eight genomes: these were individually sequenced at the 
PHE-MRU to complete MLST proﬁ les.
Genomic analysis
Population genomic analyses were done with a 
hierarchical gene-by-gene approach15,19 that enabled 
Research in context
Evidence before this study
We searched PubMed with the terms “Neisseria meningitidis”, 
“genome sequence”, and “epidemiology” to identify reports 
published in any language before the start of the April, 2014. 
We identified four studies that have reported the use of 
whole-genome-sequencing (WGS) data for retrospective 
resolution of single lineage N meningitidis outbreak or 
hyperendemic scenarios and various case studies in which 
clinical isolates were used retrospectively for strain 
characterisation. In three studies, WGS was done for 
16–108 meningococcal isolates to investigate meningococcal 
lineage structure with universally present genes. In two of 
these studies, this approach revealed robust phylogenetic 
relationships between isolates of different clonal complexes, 
which contrasted with poor within-clonal complex 
resolution. In addition to PubMLST.org, which we used in this 
study, two publically available N meningitidis comparative 
genomic databases existed, both of which included only 
previously published genomes and neither of which provided 
integrated clinical characterisation of strains or strain 
relationships.
Added value of this study
The Meningitis Research Foundation Meningococcus Genome 
Library (MRF-MGL) adds to the application of WGS in public 
health microbiology by providing an infrastructure to process, 
analyse, and interpret bacterial data in clinical settings. It 
provides a framework capable of real-time analyses of such data 
for diagnosis or for investigation of outbreaks of 
meningococcal disease in particular and other bacterial diseases 
in general. Combining the data in the MRF-MGL with previously 
published data by use of the in-built data analysis tools of 
PubMLST.org, we showed the importance of meningococcal 
lineages to changes in meningococcal epidemiology over time.
Implications of all the available evidence
Several reports have made use of the MRF-MGL data in taxonomic, 
comparative genomic (eg, core-genome delineation), and vaccine 
antigen characterisation. Data in the MRF-MGL form an invaluable 
evidence base for vaccination policy. For example, in combination 
with existing epidemiological evidence and WGS sequences, the 
data informed the introduction of meningococcal serogroup A, C, 
W, and Y conjugate vaccines into the UK immunisation schedule.
See Online for appendix
For the European Nucleotide 
Archive see www.ebi.ac.uk/ena
For the MRF-MGL Neisseria 
Sequence Typing database see 
to http://PubMLST.org/neisseria/
Articles
1422 www.thelancet.com/infection   Vol 15  December 2015
rapid, reproducible visualisation of genome similarity 
across the entire dataset.7,19 The Bacterial Isolate 
Genome Sequence Database16 Genome Comparator tool 
was used to generate allele-based distance matrices that 
were visualised as Neighbor-Net diagrams. This 
approach accounted for the high rates of recombination 
in meningococcal popu lations, without discarding 
variant loci deemed to be generated by recombination.19 
Loci missing in isolates due to absence in the genome 
or incomplete assembly were ignored in pairwise 
comparisons. Maximum-likelihood trees were recon-
structed from nucleotide sequence data extracted 
from the MRF-MGL (appendix). For comparison of 
antigenic variation, we calculated the proportions of 
aminoacids at which two compared sequences diﬀ ered 
(p distances) in antigen peptide sequences fHbp, 
NHBA, PorA, and NadA4 of meningococcal group B 
vaccine (Bexsero, GlaxoSmithKline, Brentford, 
Middlesex, UK), with complete deletion of alignment 
gaps.
Statistical analysis
Between-year relative risk ratios (RRRs) with 95% CIs 
(Wald estimates)20 were calculated with the epitools 
package, with the function epitab. Standard R functions 
were used to do χ² and Fisher’s exact tests. Human 
population data were obtained in October, 2013, from 
the UK Oﬃ  ce for National Statistics for 1996–2012 and 
from The National Archives for 1912–95. For the age-
structured analysis, patients’ ages were provided by the 
PHE-MRU. All statistical analyses were done in R 
(version 2.1.51)  with α set at 0⋅05 (appendix).
100
A
B
90
80
19
84
–8
5
19
85
–8
6
19
86
–8
7
19
87
–8
8
19
88
–8
9
19
89
–9
0
19
90
–9
1
19
91
–9
2
19
92
–9
3
19
93
–9
4
19
94
–9
5
19
95
–9
6
19
96
–9
7
19
97
–9
8
19
98
–9
9
19
99
–20
00
20
00
–0
1
20
01
–0
2
20
02
–0
3
20
03
–0
4
20
04
–0
5
20
05
–0
6
20
06
–0
7
20
07
–0
8
20
08
–0
9
20
09
–10
Lab
 co
nﬁ
rm
ed
MR
F L
ibr
ary
Lab
 co
nﬁ
rm
ed
MR
F L
ibr
ary
70
60
50
M
RU
 ca
se
s p
er
 ye
ar
 (%
)
Es
tim
at
ed
 in
cid
en
ce
 (c
as
es
 p
er
 1
00
 0
00
)
Culture-conﬁrmed cases
Year
Epidemiological year
All laboratory-conﬁrmed cases (culture and PCR conﬁrmed) 2010–11 2011–12
NG/ND
Z/E
W
X
Y
A
C
B
Capsular group
40
30
20
10
0
0
5
10
15
20
25
30
35
19
12
19
15
19
18
19
21
19
24
19
27
19
30
19
33
19
36
19
39
19
42
19
45
19
48 19
51
19
54
19
57
19
60
19
63
19
66 19
72
19
75
19
78
19
81
19
84
19
87
19
90
19
93
19
69
19
96
19
99
20
02
20
05
20
08 20
11
Figure 1: Epidemiology of meningococcal disease in England and Wales, 1912–2012
(A) Proportion of meningococcal serogroups identiﬁ ed from culture and non-culture specimens for epidemiological years 1984–85 to 2011–12. Serogroups were ascertained by serology (for isolates), 
PCR-based genotyping, or genome sequencing (for the Meningitis Research Foundation Meningococcus Genome Library). (B) Incidence of meningococcal disease. Incidence is calculated on the basis of 
notiﬁ cation data from Mary Ramsay Public Health England for 1912–97 and laboratory reports of Public Health England for 1998–2012. MRU=Meningococcal Reference Unit. Lab=laboratory. MRF=Meningitis 
Research Foundation. NG/ND=non-groupable or not determined.
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Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
The 899 genome assemblies each contained an average 
of 209 contiguous sequences and 1571 (98%) completely 
sequenced core-genome loci, which corresponded to 
around 79% of the 2000 coding sequences anticipated 
for each isolate (appendix).15 The number of alleles at 
each locus ranged from two (NEIS2089 and NEIS0627, 
hypothetical proteins) to 313 (NEIS0829, putative mem-
brane protein). The genomes comprised 272 sequence 
types, of which 219 were assigned to 20 MLST-deﬁ ned 
clonal complexes, and 498 ribosomal sequence types, 
with 56 from isolates not designated to a known clonal 
complex (appendix). N meningitidis belonging to the 
Number of isolates 
in 2010–11 (%)
Number of isolates 
in 2011–12 (%)
Ratio (2011–12: 
2010–11)
Relative risk ratio 
(95% CI)
p value
Total MRF-MGL* 501 (100%) 398 (100%) 0·79 1·09 (1·00–1·20)† 0·7
Lineage
5 (cc32) 28 (6%) 14 (4%) 0·50 0·63 (0·34–1·18)‡ 0·2
6 (cc60) 15 (3%) 5 (1%) 0·33 0·42 (0·15,1·14)‡ 0·1
23 (cc23) 60 (12%) 60 (15%) 1·00 1·26 (0·90–1·76)‡ 0·2
11 (cc11) 21 (4%) 38 (10%) 1·81 2·28 (1·36–3·82)‡ 0·002
Isolates
From patients younger than 5 years 257 (51%) 171 (43%) 0·67 0·84 (0·73–0·97)‡ 0·02
From patients aged 16–18 years 18 (4%) 27 (7%) 1·50 1·89 (1·06–3·38)‡ 0·04
Genogroup
Y 74 (15%) 67 (17%) 0·91 1·14 (0·84–1·54)‡ 0·5
C 13 (3%) 14 (4%) 1·08 1·36 (0·64–2·85)‡ 0·5
W 26 (5%) 30 (8%) 1·15 1·45 (0·87–2·41)‡ 0·2
The changes in total number of isolates, lineages, age groups, and serogroups showing the greatest variation between years are shown. MRF-MGL=Meningitis Research 
Foundation Meningococcus Genome Library. cc=clonal complex. *Total number of laboratory-conﬁ rmed cases was 1053 in 2010–11 and 766 in 2011–12 (>98% of all 
reported cases) and comprised 899 culture-conﬁ rmed cases and 920 non-culture-conﬁ rmed cases. The relative disease incidence ratio for 2011–12:2010–11 was 0·72 
(95% CI 0·66–0·79, p<0.0001, based on population sizes from the UK Oﬃ  ce for National Statistics). †All laboratory-conﬁ rmed cases. ‡Culture-conﬁ rmed cases in MRF-MGL. 
Table 1: Characteristics of the meningococcal isolates in England and Wales in 2010–11 and 2011–12
Lineage 5 (cc32)
Lineage 2·1
Lineage 2·2
100·0 cgMLST loci
BLineage 3 (cc41/44)
Lineage 32 (cc282)
Lineage 39 (cc461)
Lineage 35 (cc35)
Lineage 5 (cc32)
Lineage 2 (cc269)
Lineage 25 (cc162)
Lineage 18 (cc18)
Lineage 11 (cc11)
Lineage 22 (cc22) Cluster 1
Cluster 2
Cluster 3
4·9 rMLST loci
A
Lineage 13 (cc213)
Lineage 15 (cc1157)
Lineage 6 (cc60)
Lineage 20 (cc103) 
Lineage 14 (cc174)
Lineage 26 (cc167) 
Lineage 23 (cc23)
Figure 2: Genetic diversity of disease-associated meningococcal isolates in the Meningitis Research Foundation Meningococcus Genome Library for 
England and Wales
(A) Neighbor-Net graph showing the relationships of all 498 rMLST proﬁ les (ribosomal sequence types) within the 899 isolates available for epidemiological years 
2010–11 and 2011–2012. (B) Relationships among isolates belonging to lineage 2 (cc269; n=171) and lineage 5 (cc32) isolates (n=42) assessed with 1605 cgMLST 
loci. This analysis illustrates the improved resolution achieved with cgMLST for the substructures within and between lineages, compared with rMLST. 
rMLST=ribosomal multilocus sequence typing. cc=clonal complex. cgMLST=core-genome multilocus sequence typing.
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hyperinvasive clonal complexes 41/44 (lineage 3), 269 
(lineage 2), and 23 (lineage 23) were responsible for 
528 CCC (59%), and nine clonal complexes were rare 
(fewer than ten members). Clonal complexes varied in 
diversity (ﬁ gure 2, appendix).
Capsule groups were deduced from WGS-derived 
sequence data to provide a genogroup for each isolate. 
These were concordant with PHE-MRU sero group 
designations and PCR-derived genogroups.5 WGS data 
provided additional discrimination of the following: two 
non-groupable isolates, one possessing a capsule null 
locus and the other capsule E loci; six isolates that were 
non-groupable because loci were in phase-variable oﬀ 
status; four isolates that were assigned to serogroup and 
geno group W/Y21 that possessed serine residues at codon 
310 of the capsule polymerase, which would result in 
mixed galactose-containing or glucose-containing sialic 
acid capsules; and two serogroup B isolates that contained 
both genogroup B and E loci, although neither showed 
evidence of serogroup E expression.
668 isolates (74%) were genogroup B, 141 (16%) were 
genogroup Y, 56 (6%) genogroup W, and 27 (3%) 
genogroup C, with an additional three genogroup E 
isolates, one serogroup A isolate, one serogroup X isolate, 
and one capsule null isolate. Serogroup characteristics of 
isolates in CCC were similar to those in NCCC, with a 
slight over-representation of group Y (6%, p<0⋅0001) and 
group W (2%, p<0⋅0001) in the CCC (ﬁ gure 1). The 
proportion of CCC in older patients was slightly higher 
than that for NCCC. These diﬀ erences were consistent 
with known diﬀ erences in clinical presentation and 
diagnosis in diﬀ erent demographic groups.22,23 The 
diﬀ erences in serogroups and the proportion laboratory 
conﬁ rmed were similar in the two epidemiological years 
(table 1).
High-resolution comparisons of isolates were achieved 
by hierarchical analysis with ribosomal MLST18 and core-
genome MLST,15 as has been described previously,19 
which enabled visualisation of lineages and their 
structures (ﬁ gure 2, appendix). To take advantage of 
this high resolution, we used a proposed lineage 
nomenclature to achieve rapid identiﬁ cation of lineage 
membership by manually linking ribosomal sequence 
types to lineage and sublineage designations. Sublineages 
have so far been deﬁ ned by visual inspection and 
comparison of phenotypes, such as the ET-15 and non-
ET-15 subclusters of clonal complex 11 (lineage 11), 
which, respectively, are named lineage 11.2 and 
lineage 11.1.7,24 Maximum-likelihood trees generated from 
variable sites in ribosomal and core-genome MLST loci 
identiﬁ ed the same lineages and sublineages as allele-
based analyses (appendix). Congruence was high for 
ribosomal sequence types and core-genome MLST 
relationships, with one exception: lineage 2 sublineages 
were probably aﬀ ected by recombination of some 
ribosomal MLST loci (ﬁ gure 2, appendix).
In the two epidemiological years, nearly a quarter 
(average 102 isolates [23%]) of CCC were from individuals 
younger than 1 year, with the highest incidence seen in 
patients aged 4–6 months (average 35 isolates [8%]). The 
age characteristics for MRF-MGL isolates reﬂ ected those 
for NCCC, except for isolates from individuals older than 
30 years, in whom the proportion of CCC was slightly 
greater (an additional 0⋅01–1⋅07% for most of the 2 year 
age groups). The age distribution changed from 2010–11 
to 2011–12, with a substantial reduction being seen in 
cases from individuals younger than 5 years but a 
signiﬁ cant increase in cases from those aged 16–18 years 
in the latter year (table 1). Overall, CCC in England and 
Wales declined from 501 in 2010–11 to 398 in 2011–12 
(table 1), which was the lowest IMD incidence since the 
early 1980s (ﬁ gure 1). No speciﬁ c lineage was signiﬁ cantly 
associated with the decline in cases, although the largest 
prevalence decreases were observed in lineages 5 and 6 
(table 1). The prevalence of lineages 23 and 11 increased 
in 2011–12, as did the frequency of isolates from 
genogroups C, W, and Y (table 1).
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Figure 3: Prevalence of clonal complexes in cases of invasive meningococcal disease in England and Wales
(A) Proportion of isolates for speciﬁ c clonal complexes by age groups of patients in the MRF-MGL for 
epidemiological years 2010–11 and 2011–12. (B) Estimated yearly prevalence of major clonal complexes from 
1975 to 2012. Proportions are derived from the multilocus sequence typing data available from the Public Health 
England Meningococcal Reference Unit20 multiplied by yearly disease notiﬁ cations. MRF-MGL=Meningitis Research 
Foundation Meningococcus Genome Library. NT=multilocus sequence typing not done. ND=sequence type not 
designated to a clonal complex. cc=clonal complex.
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We noted a strong association between patients’ age 
and the lineage of N meningitidis (appendix). For example, 
the incidence of lineages 2 and 3 declined signiﬁ cantly 
with age (ﬁ gure 3). Additionally, up to age 4 years, 
infection with lineage 13 N meningitidis was less likely 
than with lineage 3 N meningitidis (RRR 0·32, 95% CI 
0·23–0·45), whereas after age 4 years patients were two 
orders of magnitude more likely to be infected with 
lineage 23 than lineage 3 (RRR 27·73 in individuals older 
than 25 years, 95% CI 12·91–59·56). After age 14 years, 
the incidence of disease caused by lineage 11 
N meningitidis increased signiﬁ cantly (RRR 7⋅17 in 
individuals older than 25 years, 95% CI 3·53–14·57). 
Disease caused by other lineages was greatest in indi-
viduals younger than 5 years and older than 30 years, 
although in the latter age group lineage 3 disease 
remained most likely (appendix). The youngest and 
oldest patients were aﬀ ected by the widest range of 
meningococcal genotypes, although four of the least 
diverse lineages (39, 25, 22, and 23) were often isolated 
from patients younger than 5 years or older than 50 years 
(ﬁ gure 3, appendix). The association of genogroup with 
patients’ age was consistent with the association with 
lineage, for example, genogroup C N meningitidis were 
more frequently identiﬁ ed in individuals aged 25–49 years 
(average 2⋅2 isolates per 2 year age group [11%]) than any 
other genogroup (average 1⋅5 isolates per 2 year age 
group [5%]; p<0⋅0001).
Vaccine antigen peptide sequences were diverse within 
the MRF-MGL. Despite possessing the greatest numbers 
of rare peptide subvariants, fHbp and NHBA were 
reasonably well conserved at the peptide sequence level 
(average p distances 0⋅20 [80% aminoacid identity] and 
0⋅13 [87% identity], respectively, table 2). PorA variable 
region 2 was highly variable (38% aminoacid identity), 
with 55 diﬀ erent peptide subvariants identiﬁ ed. The 
NadA antigen was absent in 797 MRF-MGL isolates 
(89%; table 2). Vaccine antigen variants were associated 
with particular lineages; for example, fHbp peptide 1 
(variant 1.1) was found mainly in lineage 5 isolates 
(appendix).4 Exact aminoacid sequence matches to any 
vaccine antigen variant occurred in 259 isolates (29%) 
from eight lineages. Among these, 247 (37%) of the 
668 genogroup B isolates contained at least one exact 
match to a vaccine variant. Lineage 3 was most likely to 
contain an exact match to any vaccine antigen variant 
(203 isolates), and only one lineage 2 isolate contained an 
exact match. Almost a third of isolates from patients 
younger than 1 year (62 [31%] of 203) contained exact 
peptide matches to any variant, which is consistent with 
the association of lineage 3 with this age group (ﬁ gure 3).
Discussion
 WGS technology permits genetic characterisation of 
bacterial isolates at more than 95% of their genomic loci, 
enabling uniﬁ cation of clinical, epidemiological, and 
microbiological data.15 To aﬀ ect the care of patients, 
however, these data have to be provided in an accessible 
format that can be readily interpreted by medical and 
public health practitioners. The MRF-MGL achieves this 
for a coherent national collection of IMD isolates by 
presenting WGS data in an open-access web interface 
with in-built reporting, analysis, and export options. The 
infrastructure in the Neisseria Sequence Typing database 
is used to consolidate and extend the comprehensive case 
ascertainment data and specimen collections available in 
England and Wales, where virtually all IMD isolates are 
referred to the PHE-MRU.16,19 Increasing volumes of 
WGS data will enable formal deﬁ nition of the high-
resolution population structure of N meningitidis. These 
data will be of particular use because of the changes in 
the UK meningococcal vaccine schedule, including 
vaccines that target serogroups A, C, W, and Y, and 
serogroup B meningococci.
Consistent with previous studies, IMD isolates in the 
MRF-MGL were genetically and antigenically diverse, 
with extensive evidence for the role of recombination in 
generating this diversity.25 Gene-by-gene analyses20 
rapidly and eﬀ ectively organised this diversity into 
coherent groups that were consistent with meningococcal 
Number of unique 
peptide sequence 
variants
Mean (SD) 
aminoacid 
p distance across 
all variants present
Most prevalent variant Presence of meningococcal group B vaccine 
peptide variant
Prevalent 
(n≥10)
Rare 
(n<10)
Peptide 
variant
Number (%) 
from all 
isolates 
(n=899)
Number (%) from 
genogroup B 
isolates only 
(n=668)
Peptide 
variant
Number (%) 
from all 
isolates 
(n=899)
Number (%) from 
genogroup B isolates 
only (n=668)
fHbp 12 87 0·20 (0·13) 4 159 (18%) 159 (24%) 1.1 34 (4%) 32 (5%)
NadA 3 6 0·21 (0·20) No value* 797 (89%) 530 (79%) 8 12 (1%) 2 (<1%)
NHBA 14 70 0·13 (0·04) 2 172 (19%) 172 (26%) 2 172 (19%) 172 (26%)
PorA VR2 15 40 0·62 (0·29) P1.9 137 (15%) 133 (20%) P1.4 136 (15%) 136 (20%)
MRF-MGL=Meningitis Research Foundation Meningococcus Genome Library. *Includes genome sequences where the gene was missing, contained a frame-shift 
mutation, or was incompletely assembled, being interrupted by the end of a contiguous sequence.
Table 2: Prevalence of meningococcal group B vaccine antigen peptide variants in the MRF-MGL for epidemiological years 2010–11 and 2011–12
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clonal complexes.2,15,26 We noted good agreement between 
diﬀ erent analytical approaches, which identiﬁ ed at least 
20 distinct meningococcal lineages. The lineage 
nomenclature is searchable within the Neisseria Sequence 
Typing database and the MRF-MGL, which enables 
comparisons of clonal complexes and other designations. 
In common with other geographical regions, IMD 
incidence in England and Wales has ﬂ uctuated,5,27 and, 
using the in-built analysis tools, the MRF-MGL data 
could be readily placed in the context of previous 
studies.28 The largest epidemics in the past 100 years can 
be attributed to the disruptions of the World Wars and 
were probably caused by single lineages. By contrast, the 
increase in disease incidence seen from 1985 to 2005 was 
due to concurrent and successive IMD epidemics caused 
by lineages 5, 11, 2, and 3. These observations support the 
view that later IMD epidemics have been due to 
interactions between meningococcal diversity, human 
social behaviour, and host immunity. Continued 
surveillance using WGS data will further deﬁ ne the 
N meningitidis lineages, serogroups, and genogroups 
responsible for ﬂ uctuations in incidence and provide the 
genetic resolution necessary to detect outbreaks and 
future trends in disease. Such data will provide the basis 
for development of targeted interventions.
The pronounced associations between speciﬁ c lineages 
and disease in particular age groups were consistent with 
those reported for pan-European MLST data from the 
early 2000s.23 The diversity of IMD isolates was increased 
in the oldest and youngest age groups, perhaps due to 
reduced immunity in these populations. We noted two 
important diﬀ erences in patterns, that fewer lineage 11 
isolates and more lineage 23 isolates were present in the 
MRF-MGL than in the previous European data. The 
diﬀ erence in lineage 11 serogroup C prevalence is 
attributable to the introduction of meningococcal 
serogroup C conjugate vaccines, but the reasons for 
changes in the prevalence of lineage 23 serogroup Y 
N meningitidis, aﬀ ecting mainly older individuals, are 
unclear.27,29 Identiﬁ cation of such associations alongside 
WGS data presents the prospect of investigating the 
genomic basis of meningococcal phenotypes, exempliﬁ ed 
by the over-representation of the meningococcal disease-
associated phage in lineages with a propensity to cause 
disease in adolescents.30 Comparison of WGS data from 
invasive and carried N meningitidis will improve such 
studies.
An important advantage of WGS is the high-resolution 
designation of isolate relationships within lineages, such 
as being able to distinguish sublineage 11.1 from 11.2, 
which is not possible with MLST.7 Sublineages often 
show distinct epidemiological behaviours, with 
epidemics being attributable to speciﬁ c sublineages. As 
more WGS data become available, the role of sublineages 
will become increasingly apparent, especially for those 
not resolvable by MLST. For example, lineage 11.1 isolates 
were predominant among global IMD isolates in the 
mid-20th century, but from the mid-1990s to early 2000s, 
serogroup C lineage 11.2 was the main cause of 
serogroup C disease in many countries, including the 
UK.7 This outbreak was successfully contained by herd 
immunity generated with meningococcal serogroup C 
conjugate polysaccharide vaccines,3,5 but 10–14 years after 
implementation some lineage 11.2 serogroup C disease 
is recorded in the MRF-MGL, perhaps because of waning 
immunity in adolescents.31 Serogroup C lineage 11.2 
N meningitidis has been associated with IMD outbreaks 
in several communities of men who have sex with 
men.32,33 Finally, serogroup W lineage 11.1 N meningitidis 
was introduced into England and Wales in the early 
2000s as part of the Hajj-associated outbreaks,5 but a later 
increase in lineage 11.1 serogroup W N meningitidis is 
due to a closely related but distinct variant.24
With no serogroup B conjugate polysaccharide 
vaccines, protection against serogroup B IMD depends 
on protein-based vaccines. Bexsero was introduced into 
the UK immunisation programme in late 2015. This 
vaccine contains an outer-membrane vesicle and one 
protein antigen (NHBA) from a lineage 3 N meningitidis 
with two protein antigens (fHbp and NadA) from a 
lineage 5 organism.4 Peptide sequences of vaccine 
antigens are readily deduced within the MRF-MGL, 
enabling the potential coverage of actual and proposed 
vaccine formulations to be assessed. Exact peptide 
matches to the vaccine components were rare in the 
MRF-MGL, especially in isolates from individuals 
younger than 1 year, which shows the importance of 
immunological cross-reactivity between peptide variants 
to achieve good coverage with vaccines. Cross-protection 
between fHbp variant 1 subvariants and NadA-1, NadA-2, 
and NadA-3 subvariants has been described.34 Potentially 
cross-protective fHbp subvariants were identiﬁ ed in 
497 (55%) and NadA subvariants in 97 (11%) of MRF-
MGL isolates. Therefore, 567 (63%) of the MRF-MGL, 
498 (75%) of genogroup B isolates, and all 35 of the 
lineage 11.1 genogroup W isolates, had at least one 
peptide sequence match to one of the vaccine antigens, 
which suggests that coverage is similar to that predicted 
with the meningococcal antigen typing system assay,35 
but remains subject to several assumptions. Over time, 
the ﬂ uctuations in IMD-associated meningococcal 
lineages and their antigen variants identiﬁ ed with WGS 
surveillance might warrant the development of 
alternative vaccine formulations.
Real-time genomic analyses of N meningitidis from 
individuals who have developed disease are increasingly 
feasible as technology develops: combined with the 4 day 
turnaround for WGS determination, the gene-by-gene 
approach allows genome-level characterisation of 
multiple isolates and comparisons with reference 
databases within hours.7 Furthermore, WGS involves the 
processing of individual specimens from which multiple 
types of information can be extracted, including high-
resolution genetic relatedness of isolates, variation of 
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vaccine and typing antigens, and likely vaccine and 
antimicrobial susceptibility.36 The delivery of these data 
through easily accessible interfaces will improve the 
ability to intervene in all bacterial infections from the 
level of the individual patient to entire populations. In 
the case of the N meningitidis, this will be especially 
important during the introduction of novel vaccines.
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